• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Eledon Pharmaceuticals Inc (NQ: ELDN )

    2.620 +0.070 (+2.75%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 18,387
    Open 2.520
    Bid (Size) 2.590 (4)
    Ask (Size) 2.630 (5)
    Prev. Close 2.550
    Today's Range 2.520 - 2.670
    52wk Range 1.070 - 3.349
    Shares Outstanding 22,506,956
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
    Enrollment Completed Four Months Ahead of Schedule 
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +39.36%
    +39.36%
    1 Month
    -4.38%
    -4.38%
    3 Month
    +5.22%
    +5.22%
    6 Month
    +48.86%
    +48.86%
    1 Year
    +55.03%
    +55.03%

    More News

    Read More
    ELDN Stock Earnings: Eledon Pharma Misses EPS for Q2 2024
    Via InvestorPlace
    Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) Leading the Way in Monday Trading Based on Percentage Gain
    Via Investor Brand Network
    Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues
    Via InvestorPlace
    3 High-Potential Penny Stocks to Turn $1000 into $1 Million: June 2024
    Via InvestorPlace
    Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    ELDN Stock Earnings: Eledon Pharma Beats EPS for Q1 2024
    Via InvestorPlace
    Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Nano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    ELDN Stock Earnings: Eledon Pharma Beats EPS for Q4 2023
    Via InvestorPlace
    Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Kidney Transplant From Genetically Edited Pig: Boston Patient With End-Stage Renal Disease Becomes First To Receive
    Via Benzinga
    Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.